MedTrace Logo

Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study

NCT04365764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-04-21

No results posted yet for this study

Summary

Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

Conditions

Sponsors & Collaborators

  • Centre Hospitalier Intercommunal Robert Ballanger

    collaborator OTHER

  • Centre Hospitalier Intercommunal Montfermeil-Le Raincy

    collaborator UNKNOWN

  • CMC Ambroise Paré

    collaborator OTHER

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Principal Investigators

  • Joe-Elie Salem, MD, PhD · APHP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-14
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04365764 on ClinicalTrials.gov